医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Quintiles Introduces Precision Enrollment to Enhance Patient Recruitment in Oncology Trials

2016年05月31日 PM07:45
このエントリーをはてなブックマークに追加

Smart Multimedia Gallery

 

RESEARCH TRIANGLE PARK, N.C.

Quintiles, the world’s largest provider of product development and integrated healthcare services, today announced its Precision Enrollment offering. The new enrollment model is designed to significantly accelerate site start-up and patient recruitment in oncology clinical trials working with the company’s network of investigative sites across the U.S and leveraging secondary data (e.g. electronic health records-EHRs.) In this new model, the traditional site start-up pathway is realigned so a site is only opened after a patient is identified.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160531005279/en/

“The rise of precision medicine, scarcity of patients and investigators, combined with increasingly complex trial protocols, requires innovative approaches to clinical trial implementation,” said Cynthia Verst, PharmD, president, Clinical Operations at Quintiles. “This solution harnesses Quintiles’ deep therapeutic expertise in oncology, robust oncology investigator relationships and our demonstrated operational excellence to identify and recruit the right patient, from the right investigator, for the right oncology trial at the right time.”

Today, three out of five oncology treatments are targeted therapies, with efficacy in niche patient subpopulations.1 These factors can contribute to higher screen failure rates and pose critical challenges for recruiting patients that fit a particular trial profile. Conventional models for targeting these sub-populations and pre-screening of these patients are time- and cost-intensive, making it difficult for oncologists to find the study that fits the individual patient.

With Precision Enrollment, Quintiles has built a network of oncology sites with master contracts as well as centralized IRB capabilities to streamline patient identification and start-up. The program will enable pre-identification of patients based on study and biomarker criteria, across broad geographic areas, using EHRs and other secondary data sources before a site joins a study. By using this rapid start-up model, these pre-identified patients are quickly matched to specific protocol inclusion and exclusion criteria and site activation is designed to take less than 21 days.

“Our premier site network and strong relationships with investigators is an integral part of Precision Enrollment, and this approach can provide value to both pharmaceutical companies and patients alike,” said Jeanne Hecht, senior vice president and global head, Site & Patient Networks at Quintiles. “By opening a site only after a patient has been identified, we’re able to reduce zero-enrolling sites and associated time and costs, and most importantly, provide patients with quicker access to potentially life-saving treatments.”

To learn more about Quintiles Precision Enrollment, view the video and visit quintiles.com/precisionenrollment.

About Quintiles

Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest provider of product development and integrated healthcare services, including commercial and observational solutions. Conducting operations in approximately 100 countries, Quintiles is a member of the FORTUNE 500 and has been named to FORTUNE’s list of the “World’s Most Admired Companies.” To learn more, visit www.quintiles.com.

1 McKesson Specialty Health/US Oncology Network. 2013

Click here to subscribe to Mobile Alerts for Quintiles.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160531005279/en/

CONTACT

Quintiles Media Relations
Phil Bridges, (phil.bridges@quintiles.com)
+
1.919.998.1653 (office) +1.919.457.6347 (mobile)
or
Quintiles
Investor Relations
Todd Kasper, (InvestorRelations@quintiles.com)
+1.919.998.2590

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists
  • セルトリオン、COVID-19変異株拡散の問題に取り組むべく、当社の抗体開発プラットフォームを使用して、CT-P59によるテーラーメード中和抗体カクテル療法の開発に当たる
  • Professor Juan Marchal Believes Propanc Biopharma’s Proenzyme Therapy May Offer New Treatment Opportunity for Cancer Patients
  • セルトリオンのCOVID-19治療薬候補が韓国MFDSより条件付き製造販売承認を取得
  • MED™ 3Dプリントで製造した医薬品が米国FDAよりIND承認を取得